ArticleOne health (Amsterdam, Netherlands)2026
Variability in the regulation of medically important antimicrobials among countries: A One Health approach.
Article in One health (Amsterdam, Netherlands), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The One Health approach recognizes that antimicrobial monitoring and regulations must jointly address the risks of antimicrobial resistance in human and animal health for effective strategy and policy to achieve global public health. We operationalize this principle by integrating the World Health Organization's human importance classifications with the World Organization for Animal Health's veterinary classifications to create a hierarchical framework that prioritizes human health. This framework underpins our unique "One Health Score" (OHS), to evaluate regulatory compliance of country-specific drug residue limits with international standards of Codex. Codex, the European Union, and the United States are identified as leaders of establishing maximum residue limits to which other countries defer to. Among pairs with medical classifications, 53% fall under the pairing of Highly Important Antimicrobials (H3) for humans and Veterinary Critically Important Antimicrobials (V1) for animals. The One Health Score is non-negative for at least 50% of countries at each medical importance level. However, 21% of the countries with H3V1 MRLs are laxer than Codex. Drugs with a high market demand in animal agriculture are the most commonly regulated among countries. This suggests drugs used less in food animals may not be adequately regulated currently, despite, in some cases, being highly important for human health. Country officials must balance economic and health priorities when setting or modifying drug residue limits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.